Shopping Cart
Remove All
Your shopping cart is currently empty
Mirvetuximab soravtansine
Copy Product Info
😃Good
Catalog No. T77825Cas No. 1453084-37-1
Alias TAK-853, IMGN-853, IMGN853
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
Mirvetuximab soravtansine
Mirvetuximab soravtansine
Copy Product Info😃Good
Purity: 95%
Catalog No. T77825Alias TAK-853, IMGN-853, IMGN853Cas No. 1453084-37-1
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $923 | - | In Stock | |
| 5 mg | $2,540 | - | In Stock | |
| 10 mg | $3,420 | - | In Stock | |
| 25 mg | $4,970 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.52% (SEC-HPLC)
Appearance:Liquid
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer. |
| In vitro | 8 nM Mirvetuximab soravtansine in combination with Carboplatin treated IGROV-1 cells showed enhanced synergistic inhibition of growth and disruption of the cell cycle in vitro. [1] |
| In vivo | Intravenous injection of 5 mg/kg Mirvetuximab soravtansine enhances the antitumor effect of Carboplatin in vivo using a xenograft model derived from SCID female mouse patients. [1] |
| Synonyms | TAK-853, IMGN-853, IMGN853 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <10 EU/mg |
| Conjucates | DM4 |
| Gene ID | |
| Uniprot ID | |
| Target | FOLR1/FRA |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1453084-37-1 |
| Isotype | IgG1-DM4 |
| Storage | store at low temperature | Lyophilized powder: -20~-80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Mirvetuximab soravtansine | purchase Mirvetuximab soravtansine | Mirvetuximab soravtansine cost | order Mirvetuximab soravtansine | Mirvetuximab soravtansine in vivo | Mirvetuximab soravtansine in vitro | Mirvetuximab soravtansine molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.